FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.
What happened
FDA inspected the Annonay drug manufacturing facility from January 12 to 22, 2026. The agency found that the company did not adequately investigate customer complaints about contamination—including mold, black specks, and discoloration—and that several complaint samples failed sterility testing. Inspectors also saw poor aseptic practices, blocked airflow, damaged cleanroom surfaces with water leaks, and critical equipment parts that were not sterilized between batches.
What FDA found
FDA said the company did not thoroughly investigate complaints about mold, black specks, discoloration, and sterility failures or find root causes and fix them.
21 CFR 211.192FDA said the company did not follow proper written procedures to prevent microbial contamination in sterile drugs and did not validate aseptic and sterilization processes; inspectors saw poor aseptic practices and airflow blocked during filling line setup.
21 CFR 211.113(b)FDA said floors, walls, and ceilings in aseptic areas were not smooth, hard, easily cleanable surfaces and were damaged, with water leaks and mold recoveries.
21 CFR 211.42(c)(10)(i) and 211.42(c)(10)(vi)FDA said the company lacked an adequate cleaning and disinfection system for aseptic rooms and equipment and did not sterilize critical equipment parts between batches, using disinfectant instead.
21 CFR 211.42(c)(10)(v)
What FDA wants
FDA tells the company to provide independent assessments and detailed CAPA plans for complaint investigations, aseptic processing and contamination hazards, container-closure suitability, facility and equipment maintenance, cleaning and disinfection, and a three-year complaint table. FDA also says the response must address ceasing U.S. manufacture of the affected drug products until facility and equipment remediations are complete; no response deadline is stated in the provided letter text.
Who should pay attention
- brands that rely on this contract manufacturer for sterile drugs
- U.S. distributors of sterile OTC and prescription products
- supplier quality teams reviewing container-closure and complaint data
This is a summary. Read the original letter on fda.gov.